Its only bad if you have only one pharma intereste

Its only bad if you have only one pharma interested..there will be several pharmas interested, especially if that topline NASH report looks strong. There is very little competition from anything in trials for this disease whereas Cancer is a crowded space with a lot of options. thats why Dr K said they want a partner for NASH. The trial is going to be very expensive but if we negotiate well here, the pharma should buy 10 percent of the company plus foot the bill for the trial. once the trial looks good and we are at the BLA level perhaps the licensing agreement gets signed which would bring in 10's of millions if not more plus the percentage of sales.